摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(3-methoxyphenyl)-5-methyl-4H-[1,2,4]triazole | 1152849-91-6

中文名称
——
中文别名
——
英文名称
3-(3-methoxyphenyl)-5-methyl-4H-[1,2,4]triazole
英文别名
5-(3-Methoxyphenyl)-3-methyl-1H-1,2,4-triazole;3-(3-methoxyphenyl)-5-methyl-1H-1,2,4-triazole
3-(3-methoxyphenyl)-5-methyl-4H-[1,2,4]triazole化学式
CAS
1152849-91-6
化学式
C10H11N3O
mdl
——
分子量
189.217
InChiKey
FYZLKPKLEOIPQW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    50.8
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • SMALL MOLECULE MODULATORS OF CELL ADHESION
    申请人:Gupta Mukur
    公开号:US20090291967A1
    公开(公告)日:2009-11-26
    Compounds, particularly compounds having activity as modulators of cadherin-mediated cell adhesion having the following structure: or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, X, Y, Z, m and n are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed.
    化合物,特别是具有作为调节cadherin介导的细胞粘附活性的化合物,具有以下结构:或其药用盐、立体异构体或前药,其中R1、R2、R3、R4、R5、R6、A、X、Y、Z、m和n如本文所定义。与其制备和使用相关的方法,以及含有该化合物的药物组合物也被披露。
  • [EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2014057435A1
    公开(公告)日:2014-04-17
    The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    本发明涉及公式(I)中的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-甲酮衍生物,其中R和环A1、A2和A3如描述中所述,以及其药用盐,其制备方法,含有一个或多个公式(I)化合物的药物组合物,以及它们作为药物的用途,特别是作为促进睡眠荷尔蒙受体拮抗剂的用途。
  • OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:US20150252032A1
    公开(公告)日:2015-09-10
    The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    本发明涉及公式(I)的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone衍生物,其中R和环A1A2和A3如描述中所述,以及其药学上可接受的盐、其制备方法、含有一个或多个公式(I)化合物的制药组合物以及它们作为药物的用途,特别是作为促进睡眠激素受体拮抗剂的用途。
  • US9493446B2
    申请人:——
    公开号:US9493446B2
    公开(公告)日:2016-11-15
查看更多